Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma -A randomized double blind study
Phase 1
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000001732
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients judged inappropriated by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method immunologicalresponse and clinical efficacy